Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Guidance, and Preferred Stock Conversion

INTERPACE BIOSCIENCES, INC.

Preliminary 2025 thyroid testing revenue of ~$34-35M, up 21% over prior year.
Company initiates 2026 revenue guidance of ~$40M, representing 16% growth in thyroid testing.
All outstanding Series C Preferred Stock converted into common stock at $2.02 per share, issuing ~23.3M shares.
Company is debt-free with positive net income and EBITDA, plans to seek uplisting to Nasdaq in 2026.
Following conversion, pro forma basic shares outstanding ~27.7M; 1315 Capital owns ~34%, Ampersand owns ~50%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.